CDK4 and breast cancer: In BC cell lines, Litchfield et al. reported that abemaciclib can inhibit mTOR by blocking both PIM kinases and CDK4/6, which resulted in blocking the PI3K/Akt/mTOR pathway and reduced cell growth.